Table 3. Summary of Reactome pathway enrichment results for the 771 genes represented in both mouse and human embryonic developing lung characteristic subtranscriptomes.
Entities refer to proteins, molecules, sequences, and other physical complexes associated with a given pathway in Reactome database; entities found are those associated with input gene sets and total entities refers to all entities in a given pathway. FDR represents multiple testing corrected p-values for enrichment.
| Entities found | Entities total | Percent total | FDR | |
|---|---|---|---|---|
| Cell cycle | 92 | 608 | 15.1% | 8.97 × 10−14 |
| Cell cycle checkpoints | 22 | 169 | 13.0% | 1.80 × 10−2 |
| ATR response to replication stress | 8 | 39 | 20.5% | 4.77 × 10−2 |
| Mitotic G1-G1/S phases | 21 | 139 | 15.1% | 4.46 × 10−3 |
| Pre-replicative complex activation | 8 | 33 | 24.2% | 2.76 × 10−2 |
| Mitotic G2-G2/M phases | 23 | 141 | 16.3% | 7.50 × 10−4 |
| Polo-like kinase-mediated events | 9 | 23 | 39.1% | 6.70 × 10−4 |
| S phase | 16 | 140 | 11.4% | 9.08 × 10−2 |
| M phase | 51 | 316 | 16.1% | 2.84 × 10−8 |
| Resolution chromatid cohesion | 27 | 128 | 21.1% | 1.83 × 10−6 |
| Metabolism | 135 | 3,163 | 4.3% | 1.00 × 101 |
| Erythrocyte gas exchange | 4 | 16 | 25.0% | 1.40 × 10−1 |
| Surfactant metabolism | 7 | 52 | 13.5% | 1.96 × 10−1 |
| Immune system | 132 | 1,841 | 7.2% | 6.69 × 10−2 |
| Adaptive immune system | 75 | 1,002 | 7.5% | 1.18 × 10−1 |
| TCR signaling | 25 | 145 | 17.2% | 1.63 × 10−4 |
| MHC-II antigen presentation | 30 | 141 | 21.3% | 3.20 × 10−7 |
| Costimulation by CD28 family | 24 | 96 | 25.0% | 5.42 × 10−7 |
| PD-1 signaling | 17 | 45 | 37.8% | 3.20 × 10−7 |
| Cytokine signaling in immunity | 68 | 678 | 10.0% | 5.66 × 10−4 |
| Interferon signaling | 35 | 289 | 12.1% | 2.43 × 10−3 |
| Interferon gamma signaling | 21 | 138 | 15.2% | 3.77 × 10−2 |
| Antiviral mechanism IFN-stimulated | 13 | 83 | 15.7% | 3.60 × 10−2 |
| Interleukin signaling | 31 | 358 | 8.7% | 1.56 × 10−1 |
| DAP12 signaling | 33 | 364 | 9.1% | 9.02 × 10−2 |
| Developmental biology | 86 | 904 | 9.5% | 8.68 × 10−6 |
| Axon guidance | 66 | 568 | 11.6% | 8.68 × 10−6 |
| L1CAM interactions | 16 | 124 | 12.9% | 5.66 × 10−2 |
| NCAM signaling (neurite out-growth) | 29 | 298 | 9.7% | 6.69 × 10−2 |
| Semaphorin interactions | 11 | 73 | 15.1% | 6.69 × 10−2 |
| Signaling by robo receptor | 8 | 38 | 21.1% | 4.44 × 10−2 |
| Signal transduction | 211 | 2,710 | 7.79% | 3.42 × 10−1 |
| PIP3 Activates AKT sgnaling | 15 | 121 | 12.4% | 6.69 × 10−2 |
| IRS-mediated sgnaling | 28 | 306 | 9.2% | 1.21 × 10−1 |
| SCF-KIT sgnaling | 34 | 339 | 10.0% | 3.94 × 10−2 |
| EGFR signaling | 38 | 376 | 10.1% | 2.76 × 10−2 |
| FGFR signaling | 33 | 356 | 9.3% | 7.44 × 10−2 |
| PDGF signaling | 38 | 392 | 9.7% | 3.88 × 10−2 |
| ERBB2 signaling | 33 | 360 | 9.2% | 8.04 × 10−2 |
| ERBB4 signaling | 34 | 345 | 9.9% | 4.77 × 10−2 |
| Rho GT pase signaling | 64 | 418 | 15.3% | 1.52 × 10−9 |
| NGF signaling | 43 | 478 | 9.0% | 6.29 × 10−2 |
| Wnt signaling | 35 | 326 | 10.7% | 1.74 × 10−2 |
| IGF1R signaling | 29 | 311 | 9.3% | 9.40 × 10−2 |